Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.

Expert review of pharmacoeconomics & outcomes research - 1 Jan 2016

Gimeno-Ballester Vicente, Mar Javier, San Miguel Ramón

Abstract excerpt

BACKGROUND: The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. AIM: To estimate the cost-effectiveness of simeprevir/daclatasvir (SMV/DCV) therapy in treatment-naïve chronic hepatitis C genotype-1b patients with moderate fibrosis. METHODS: A Markov model was developed to simulate the natural history of chronic hepatitis C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Health Care Costs

Share to Imidazoles

Share to Markov Chains

Share to Pyrrolidines

Share to Quality-Adjusted Life Years

Share to Simeprevir

Source

Identifiers

PMID: 26327360
DOI: 10.1586/14737167.2015.1081061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.PMID 26327360Read ↗

[Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].Semantic proximity Read ↗

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.Semantic proximity Read ↗

Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.Semantic proximity Read ↗

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.Semantic proximity Read ↗

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.Semantic proximity Read ↗

Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.Semantic proximity Read ↗

Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1bSemantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Semantic proximity Read ↗

Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.Semantic proximity Read ↗

The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.Semantic proximity Read ↗

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.